Glycoprotein (GP) VI is the major platelet collagen receptor and a promising anti-thrombotic target. This was first demonstrated in mice using the rat monoclonal antibody JAQ1, which completely blocks the Collagen-Related Peptide (CRP)-binding site on mouse GPVI and efficiently inhibits mouse platelet adhesion, activation and aggregation on collagen. Here, we show for the first time that JAQ1 cross-reacts with human GPVI (huGPVI), but not with GPVI in other tested species, including rat, rabbit, guinea pig, swine, and dog. We further demonstrate that JAQ1 differently modulates mouse and human GPVI function. Similar to its effects on mouse GPVI (mGPVI), JAQ1 inhibits CRP-induced activation in human platelets, whereas, in stark contrast to mouse GPVI, it does not inhibit the adhesion, activation or aggregate formation of human platelets on collagen, but causes instead an increased response. This effect was also seen with platelets from newly generated human GPVI knockin mice (). These results indicate that the binding of JAQ1 to a structurally conserved epitope in GPVI differently affects its function in human and mouse platelets.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369317 | PMC |
| http://dx.doi.org/10.3390/ijms23158610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Isorhynchophylline inhibits platelet activation and thrombus formation.
J Cardiovasc Pharmacol
December 2024
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Article Synopsis
- Isorhynchophylline, a Chinese herbal medicine, shows anti-inflammatory and neuroprotective effects, but its impact on platelet function was previously unknown.
- The study found that isorhynchophylline reduces platelet aggregation and activation in a dose-dependent manner and does not affect surface levels of key receptors.
- In vivo tests on mice indicated that isorhynchophylline impairs hemostatic function and thrombus formation, suggesting it might be useful for treating thrombotic and cardiovascular diseases.
Human B-cells can form Hetero-aggregates with Blood Platelets: A Novel Insight into Adaptive Immunity Regulation in Multiple Sclerosis.
J Mol Biol
November 2024
University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biochemistry, Pomorska 141/143, 90-236 Lodz, Poland.
Article Synopsis
- - Multiple sclerosis (MS) is an autoimmune disease that leads to inflammation and damage to nerve tissues, and this study investigates the interactions between blood platelets and immune cells (leukocytes) in MS patients.
- - Researchers found that there is a significant increase in the movement of leukocytes towards platelets in MS, indicating that these immune interactions are enhanced, particularly in patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS).
- - The study highlights the importance of the CD40-CD40L pathway in the communication between platelets and B-cells, suggesting that this interaction may play a key role in the progression of MS and could be a target for future therapeutic strategies.
A Novel P-III Metalloproteinase from Venom Degrades Extracellular Matrix Proteins, Inhibits Platelet Aggregation, and Disrupts Endothelial Cell Adhesion via α5β1 Integrin Receptors to Arginine-Glycine-Aspartic Acid (RGD)-Containing Molecules.
Toxins (Basel)
November 2024
Laboratório de Matriz Extracelular e Biotecnologia de Venenos, Universidade Federal do Paraná, UFPR, Curitiba 81531-980, Brazil.
Article Synopsis
- Viperid snake venoms contain metalloproteinases like barnettlysin-III (Bar-III), which cause bleeding and disrupt blood clotting and tissue integrity in victims.
- Bar-III, a specific type of metalloproteinase, has been characterized in terms of its properties, including its activity being enhanced by calcium and inhibited by zinc, and its ability to degrade important blood and tissue proteins.
- The study also highlights Bar-III’s effects on platelets and endothelial cells, suggesting that it affects platelet aggregation and cell adhesion, providing insights that could lead to new treatments for snakebite envenomation.
Ischemia/reperfusion injury in acute human and experimental stroke: focus on thrombo-inflammatory mechanisms and treatments.
Neurol Res Pract
November 2024
Department of Neurology, University Hospital Wurzburg, Josef-Schneider-Str. 11, 97080, Wurzburg, Germany.
Background: Despite high recanalization rates of > 90% after endovascular thrombectomy (EVT) clinical outcome in around 50% of treated acute ischemic stroke (AIS) patients is still poor. Novel treatments augmenting the beneficial effects of recanalization are eagerly awaited, but this requires mechanistic insights to explain and overcome futile recanalization.
Main Body: At least two mechanisms contribute to futile recanalization after cerebral large vessel occlusions (LVO): (i) the no reflow phenomenon as evidenced by randomly distributed areas without return of blood flow despite reperfusion of large cerebral arteries, and (ii) ischemia/reperfusion (I/R) injury, the paradoxically harmful aspect of blood flow return in transiently ischemic organs.
GPVI-mediated thrombus stabilization of shear-induced platelet aggregates in a microfluidic stenosis.
Biophys J
November 2024
Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania; Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania. Electronic address:
Supraphysiological shear rates (>2000 s) amplify von Willebrand factor unfurling and increase platelet activation and adhesion. These elevated shear rates and shear rate gradients also play a role in shear-induced platelet aggregation (SIPA). The primary objective of this study is to investigate the contributions of major binding receptors to platelet deposition and SIPA in a stenotic model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!